BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...labs. In point-of-care settings, the test detects antigen-specific IgM after seven days of symptoms and IgG...
BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

...to the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test from Quanterix Corp. (NASDAQ:QTRX) to detect anti-spike IgG...
...MediTech Ltd. Osmotica Pharmaceutical Corp. U.S. Food and Drug Administration (FDA) Novartis AG Cancer Autoimmune Musculoskeletal Neuroendocrine tumors Multiple sclerosis (MS) covid19 covid-19 cov19dx chs2020 bee2021 Simoa Semi-Quantitative SARS-CoV-2 IgG...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

U.S. secures an additional 100M doses of Pfizer-BioNTech vaccinePfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) entered an agreement to supply the U.S. government with an additional 100 million doses of BNT162b2 for $1.95 billion, bringing...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Nov 24, 2020
Product Development

ASH preview & long shot drug pricing rules: a BioCentury podcast

On the latest edition of the BioCentury This Week podcast, BioCentury editors discuss how emerging targets, modalities and indications are stacking up at the upcoming American Society of Hematology meeting, as well as the uncertain...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...Stanford University scientists found a unique anti-SARS-CoV-2 IgG...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

Abstracts at SITC and ASH are providing more data points on the efficacy of CD47 inhibitors, and the evidence suggests the target may hold promise in solid as well as liquid tumors. Known as a...
BioCentury | Nov 7, 2020
Emerging Company Profile

IgGenix: antibody engineering for food allergies

...for allergen binding. “IgE is the rarest of antibody classes. It’s orders of magnitude lower than IgG...
...but it uses a different antibody starting point than IgGenix. The big biotech is developing IgG...
...in Phase I. According to Croote, working from IgE antibodies has an advantage over using an IgG...
Items per page:
1 - 10 of 3177
BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...labs. In point-of-care settings, the test detects antigen-specific IgM after seven days of symptoms and IgG...
BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

...to the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test from Quanterix Corp. (NASDAQ:QTRX) to detect anti-spike IgG...
...MediTech Ltd. Osmotica Pharmaceutical Corp. U.S. Food and Drug Administration (FDA) Novartis AG Cancer Autoimmune Musculoskeletal Neuroendocrine tumors Multiple sclerosis (MS) covid19 covid-19 cov19dx chs2020 bee2021 Simoa Semi-Quantitative SARS-CoV-2 IgG...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

U.S. secures an additional 100M doses of Pfizer-BioNTech vaccinePfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) entered an agreement to supply the U.S. government with an additional 100 million doses of BNT162b2 for $1.95 billion, bringing...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Nov 24, 2020
Product Development

ASH preview & long shot drug pricing rules: a BioCentury podcast

On the latest edition of the BioCentury This Week podcast, BioCentury editors discuss how emerging targets, modalities and indications are stacking up at the upcoming American Society of Hematology meeting, as well as the uncertain...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...Stanford University scientists found a unique anti-SARS-CoV-2 IgG...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

Abstracts at SITC and ASH are providing more data points on the efficacy of CD47 inhibitors, and the evidence suggests the target may hold promise in solid as well as liquid tumors. Known as a...
BioCentury | Nov 7, 2020
Emerging Company Profile

IgGenix: antibody engineering for food allergies

...for allergen binding. “IgE is the rarest of antibody classes. It’s orders of magnitude lower than IgG...
...but it uses a different antibody starting point than IgGenix. The big biotech is developing IgG...
...in Phase I. According to Croote, working from IgE antibodies has an advantage over using an IgG...
Items per page:
1 - 10 of 3177